TuisMOLN • NASDAQ
add
Molecular Partners AG
Vorige sluiting
$4,34
Dagwisseling
$4,20 - $4,43
Jaarwisseling
$3,36 - $5,36
Markkapitalisasie
165,89 m USD
Gemiddelde volume
3,43 k
P/V-verhouding
-
Dividend-opbrengs
-
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 4,48 m | -16,15% |
Netto inkomste | -12,65 m | -12,62% |
Netto winsgrens | — | — |
Wins per aandeel | -0,36 | -20,00% |
EBITDA | -12,44 m | 14,47% |
Effektiewe belastingkoers | -0,03% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 93,06 m | -37,73% |
Totale bates | 102,11 m | -35,59% |
Totale aanspreeklikheid | 21,77 m | 28,90% |
Totale ekwiteit | 80,33 m | — |
Uitstaande aandele | 37,79 m | — |
Prys om te bespreek | 2,04 | — |
Opbrengs op bates | -29,56% | — |
Opbrengs op kapitaal | -34,98% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -12,65 m | -12,62% |
Kontant van bedrywe | -11,15 m | 15,49% |
Kontant van beleggings | 11,95 m | 365,95% |
Kontant van finansiering | -300,00 k | -101,96% |
Netto kontantverandering | 294,00 k | 115,65% |
Beskikbare kontantvloei | -6,65 m | -4,92% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
153
